AU2023236291A1 - Bifunctional small molecules to target the selective degradation of circulating proteins - Google Patents

Bifunctional small molecules to target the selective degradation of circulating proteins Download PDF

Info

Publication number
AU2023236291A1
AU2023236291A1 AU2023236291A AU2023236291A AU2023236291A1 AU 2023236291 A1 AU2023236291 A1 AU 2023236291A1 AU 2023236291 A AU2023236291 A AU 2023236291A AU 2023236291 A AU2023236291 A AU 2023236291A AU 2023236291 A1 AU2023236291 A1 AU 2023236291A1
Authority
AU
Australia
Prior art keywords
compound
disease
group
certain embodiments
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023236291A
Other languages
English (en)
Inventor
David CAIANIELLO
David Spiegel
Mengwen ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by Yale University filed Critical Yale University
Publication of AU2023236291A1 publication Critical patent/AU2023236291A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023236291A 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins Pending AU2023236291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/695,645 2022-03-15
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
AU2023236291A1 true AU2023236291A1 (en) 2024-10-03

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023236291A Pending AU2023236291A1 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
US12364766B2 (en) * 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CN113301925A (zh) * 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
IL294515A (en) * 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins

Also Published As

Publication number Publication date
JP2025509730A (ja) 2025-04-11
EP4493222A2 (en) 2025-01-22
MX2024011338A (es) 2024-12-06
CN119255822A (zh) 2025-01-03
WO2023178202A2 (en) 2023-09-21
IL315579A (en) 2024-11-01
WO2023178202A3 (en) 2023-10-26
KR20240166514A (ko) 2024-11-26

Similar Documents

Publication Publication Date Title
US20250332274A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
US20240083859A1 (en) Bi-functional Molecules To Degrade Circulating Proteins
US12485178B2 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
WO2023178199A2 (en) Targeted bifunctional degraders
US12083181B2 (en) Bi-functional molecules to degrade circulating proteins
EP4493222A2 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
CA3226492A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
EA039074B1 (ru) Жирные кислоты и их конъюгаты с биомолекулами
AU2024264049A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
UA127808C2 (uk) Похідна пладієноліду (варіанти) як засіб, що здійснює цілеспрямований вплив на сплайсосому, для лікування раку
WO2023178179A2 (en) Bi-functional molecules to degrade circulating proteins
HK40042237A (en) Bifunctional small molecules to target the selective degradation of circulating proteins
WO2024067477A1 (zh) 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
EP4658263A2 (en) Compounds and methods for treating, ameliorating, or preventing arthritis